Experts
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance.
The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
Check up: COVID-19 is back in fashion
Experts
Scopo’s health powerplays: The cash caboose keeps rolling on
Health & Biotech
The Recce Pharmaceuticals director that bet the house and it’s paying off
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
10 at 10: These ASX stocks are an awestriking sight this morning
News
Rise and Shine: What you need to know before the ASX opens
News
Rise and Shine: What you need to know before the ASX opens
Explainers
The 100 best performing ASX stocks in FY20
Health & Biotech
Bondi backpackers rejoice! Recce may have a gonorrhoea cure
Health & Biotech
Bugkillers: These 2 stocks upped the ante in their bug battles this morning
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Even bacteria fighter Next Science is feeling the coronavirus pinch
Health & Biotech
Bug killers: Zoono has become a 13-bagger in 4 months as China seeks a coronavirus solution
Health & Biotech
Sepsis has tripled in Australia and these small caps are tackling it head on
Director Trades
The most noteworthy directors trades of 2019
Health & Biotech
Health: Fricken lasers shrink ovarian cancer (also look good on sharks)
News